Search

Your search keyword '"Catalano, Lucio"' showing total 20 results
Start Over Author "Catalano, Lucio" Publisher springer science and business media llc
20 results on '"Catalano, Lucio"'

1. Italian guidelines on management of persons with multimorbidity and polypharmacy

Author

Onder, Graziano, primary, Vetrano, Davide Liborio, additional, Palmer, Katie, additional, Trevisan, Caterina, additional, Amato, Laura, additional, Berti, Franco, additional, Campomori, Annalisa, additional, Catalano, Lucio, additional, Corsonello, Andrea, additional, Kruger, Paola, additional, Medea, Gerardo, additional, Nobili, Alessandro, additional, Trifirò, Gianluca, additional, Vecchi, Simona, additional, Veronese, Nicola, additional, and Marengoni, Alessandra, additional

Published
2022
Full Text
View/download PDF

4. Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

Author

Musto, Pellegrino, primary, Simeon, Vittorio, additional, Cascavilla, Nicola, additional, Falcone, Antonietta, additional, Petrucci, Maria Teresa, additional, Cesini, Laura, additional, Di Raimondo, Francesco, additional, Conticello, Concetta, additional, Ria, Roberto, additional, Catalano, Lucio, additional, Salvatore, Dalila, additional, Mastrullo, Lucia, additional, Gagliardi, Alfredo, additional, Villani, Oreste, additional, Pietrantuono, Giuseppe, additional, D’Arena, Giovanni, additional, Mansueto, Giovanna, additional, Bringhen, Sara, additional, Genuardi, Mariella, additional, Di Renzo, Nicola, additional, Reddiconto, Giovanni, additional, Fragasso, Alberto, additional, Caravita, Tommaso, additional, Scapicchio, Daniele, additional, Marziano, Gioacchino, additional, Boccadoro, Mario, additional, Mangiacavalli, Silvia, additional, and Corso, Alessandro, additional

Published
2018
Full Text
View/download PDF

12. Amyloid in bone marrow smears of patients affected by multiple myeloma

Author

Petruzziello, Fara, primary, Zeppa, Pio, additional, Catalano, Lucio, additional, Cozzolino, Immacolata, additional, Gargiulo, Giuseppe, additional, Musto, Pellegrino, additional, D’Auria, Fiorella, additional, Liso, Vincenzo, additional, Rizzi, Rita, additional, Caruso, Nadia, additional, Califano, Catello, additional, Piro, Eugenio, additional, Musso, Maurizio, additional, Bonanno, Vincenza, additional, Pia Falcone, Antonietta, additional, Tafuto, Salvatore, additional, Di Raimondo, Francesco, additional, De Laurentiis, Michelino, additional, Pane, Fabrizio, additional, Palombini, Lucio, additional, and Rotoli, Bruno, additional

Published
2009
Full Text
View/download PDF

13. Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis

Author

Catalano, Lucio, primary, Del Vecchio, Silvana, additional, Petruzziello, Fara, additional, Fonti, Rosa, additional, Salvatore, Barbara, additional, Martorelli, Carmen, additional, Califano, Catello, additional, Caparrotti, Giuseppe, additional, Segreto, Sabrina, additional, Pace, Leonardo, additional, and Rotoli, Bruno, additional

Published
2007
Full Text
View/download PDF

15. Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up

Author

Pace, Leonardo, primary, Catalano, Lucio, additional, Del Vecchio, Silvana, additional, Di Gennaro, Francesca, additional, De Renzo, Amalia, additional, Sica, Giulia, additional, Califano, Catello, additional, Tedesco, Nicolina, additional, Borrelli, Giovanni, additional, Rotoli, Bruno, additional, and Salvatore, Marco, additional

Published
2001
Full Text
View/download PDF

17. Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

Author

Nicola Di Renzo, Concetta Conticello, Lucia Mastrullo, Giovanni Reddiconto, Alberto Fragasso, Daniele Scapicchio, Roberto Ria, Maria Teresa Petrucci, Gioacchino Marziano, Nicola Cascavilla, Alfredo Gagliardi, Vittorio Simeon, Silvia Mangiacavalli, Alessandro Corso, Giovanni D'Arena, Francesco Di Raimondo, Giovanna Mansueto, Lucio Catalano, Antonietta Falcone, Pellegrino Musto, Laura Cesini, Tommaso Caravita, Sara Bringhen, Giuseppe Pietrantuono, Oreste Villani, Dalila Salvatore, Mariella Genuardi, Mario Boccadoro, Musto, Pellegrino, Simeon, Vittorio, Cascavilla, Nicola, Falcone, Antonietta, Petrucci, Maria Teresa, Cesini, Laura, Di Raimondo, Francesco, Conticello, Concetta, Ria, Roberto, Catalano, Lucio, Salvatore, Dalila, Mastrullo, Lucia, Gagliardi, Alfredo, Villani, Oreste, Pietrantuono, Giuseppe, D'Arena, Giovanni, Mansueto, Giovanna, Bringhen, Sara, Genuardi, Mariella, Di Renzo, Nicola, Reddiconto, Giovanni, Fragasso, Alberto, Caravita, Tommaso, Scapicchio, Daniele, Marziano, Gioacchino, Boccadoro, Mario, Mangiacavalli, Silvia, and Corso, Alessandro

Subjects
Male, Oncology, medicine.medical_specialty, Salvage therapy, Myeloma, First relapse, Disease-Free Survival, Bortezomib, Re-treatment, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Internal medicine, medicine, Humans, Survival rate, Multiple myeloma, Aged, Retrospective Studies, Salvage Therapy, Hematology, business.industry, Female, Follow-Up Studies, Middle Aged, Multiple Myeloma, Survival Rate, Retrospective cohort study, General Medicine, medicine.disease, 030220 oncology & carcinogenesis, Observational study, business, 030215 immunology, medicine.drug
Abstract

Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71%, including 40% partial responses, 24% very good partial responses, and 7% complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15 months, while median PFS2 was 55 months. With a median follow-up of 56 months, overall survival was 94 months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib.

Published
2018

18. Safety and comfort of domestic bortezomib injection in real-life experience

Author

Maria Di Perna, Anna Emanuele Pareto, Lucio Catalano, Claudio Cerchione, Irene Zacheo, Davide Nappi, Fabrizio Pane, Marco Picardi, Cerchione, Claudio, Nappi, Davide, Pareto, Anna Emanuele, Di Perna, Maria, Zacheo, Irene, Picardi, Marco, Pane, Fabrizio, and Catalano, Lucio

Subjects
Male, medicine.medical_specialty, Injections, Subcutaneous, Antineoplastic Agents, Disease, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Quality of life, medicine, Humans, Subcutaneou, Intensive care medicine, Adverse effect, Multiple myeloma, Aged, Aged, 80 and over, business.industry, Middle Aged, medicine.disease, Discontinuation, Regimen, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Concomitant, Quality of Life, Female, Safety, Multiple Myeloma, business, Supportive care, 030215 immunology, medicine.drug
Abstract

Despite novel agents, multiple myeloma is still an incurable disease, especially for elderly and frail patients, who are difficult to manage for concomitant comorbidities as the therapeutic options are limited and the response to chemotherapy is often short. We report our evaluations upon safety and efficacy of domestic subcutaneous bortezomib in elderly and frail patients candidate to bortezomib-melphalan-prednisone (VMP) regimen. We confirmed that overall incidence of adverse events, including peripheral neuropathy, was low, and in no case required admission to emergency service, contributing to reduce the rate of therapy discontinuation. These results confirm the effectiveness and safety of subcutaneous bortezomib, in a real-life-experience, and define a new possibility of safe auto-administration in a comfortable domestic setting. We suggest that domestic treatment can significantly improve the quality of life of the patients, avoiding unnecessary transfer to the hospital without reducing treatment efficacy.

Published
2018

19. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience

Author

Marco Picardi, Claudio Cerchione, Roberta Della Pepa, Maria Di Perna, Fabrizio Pane, Lucio Catalano, Novella Pugliese, Amalia De Renzo, Cerchione, Claudio, DE RENZO, Amalia, DI PERNA, Maria, Pepa, Roberta Della, Pugliese, Novella, Catalano, Lucio, Pane, Fabrizio, and Picardi, Marco

Subjects
Adult, Male, Bendamustine, medicine.medical_specialty, Filgrastim, medicine.medical_treatment, Polyethylene Glycols, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, medicine, Indolent Non-Hodgkin Lymphoma, Clinical endpoint, Bendamustine Hydrochloride, Humans, Prospective Studies, 030212 general & internal medicine, Aged, Febrile Neutropenia, Chemotherapy, business.industry, Lymphoma, Non-Hodgkin, Middle Aged, medicine.disease, Recombinant Proteins, Oncology, 030220 oncology & carcinogenesis, Immunology, Quality of Life, Female, Original Article, Rituximab, business, Febrile neutropenia, Pegfilgrastim, medicine.drug
Abstract

Background In this prospective study, the impact of granulocyte colony-stimulating factors (G-2 CSF) administered during induction treatment with bendamustine plus rituximab for indolent non- Hodgkin Llymphoma (NHL) was evaluated by comparing patients who received secondary prophylaxis with filgrastim (control group) versus. patients who received pegfilgrastim as primary prophylaxis (peg-group). The primary endpoint was the incidence rate of febrile neutropenia (FN)- related chemotherapy disruptions (regarding dose-dense and/or dose-intensity of schedule). The Ssecondary endpoint included days of hospitalization due to FN, and G-CSF-related side effects (grade ≥3 WHO toxicity criteria) in each group. Methods One hundred twenty-two: 122 consecutive patients, with untreated indolent NHL, were referred to our outpatient unit for remission induction immuno-chemotherapy with bendamustine-rituximab. During the first period, 61 patients received secondary prophylaxis with filgrastim, given “on demand” if ANC was

Published
2016

20. Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support

Author

Roberta Della Pepa, Claudio Cerchione, Amalia De Renzo, Fabrizio Pane, Maria Di Perna, Marco Picardi, Novella Pugliese, Davide Nappi, Lucio Catalano, Cerchione, Claudio, De Renzo, Amalia, Nappi, Davide, Di Perna, Maria, Pepa, Roberta Della, Pugliese, Novella, Catalano, Lucio, Pane, Fabrizio, and Picardi, Marco

Subjects
Bendamustine, medicine.medical_specialty, Filgrastim, business.industry, Hematologic Neoplasms, medicine.disease, Polyethylene Glycols, Granulocyte colony-stimulating factor, Bendamustine hydrochloride, Oncology, Internal medicine, Granulocyte Colony-Stimulating Factor, medicine, Bendamustine Hydrochloride, Humans, business, Pegfilgrastim, Febrile neutropenia, Aged, Febrile Neutropenia, medicine.drug
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results